So, about a $7 million market cap, with $40 million in cash and a tangible book value of around $25 million, with upcoming trials in MS and Fragile X??
Wow, that would be very harsh! There would be a sell off no doubt and it would probably over sell initially with a bounce back to something close to more reasonable all things considered, IMHO... I think NTRP had about twice the number of shares and maybe less in cash? And NTRP didn't have the additional trials on deck...
I sincerely would think that they could go to a big pharma and get something like $50 million (half of which is already there in cash) for everything, including licenses, patents, etc....
News 
Market Data 
Discover 
